Abnormal Hemoglobin Synthesis -- Mechanism and Detection
血红蛋白合成异常——机制与检测
基本信息
- 批准号:6768670
- 负责人:
- 金额:$ 43.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1976
- 资助国家:美国
- 起止时间:1976-08-01 至 2006-04-30
- 项目状态:已结题
- 来源:
- 关键词:adeno associated virus groupclinical researchdiagnosis design /evaluationdiagnostic testsdisease /disorder modelerythrocytesflow cytometrygene expressiongene mutationgene targetinggenetic disorder diagnosisgenetic promoter elementgenetically modified animalshemoglobinhemoprotein biosynthesishuman fetus tissuehuman genetic material taglaboratory mousephage displaypostmortemprenatal diagnosissickle cell anemiathalassemiatransfection /expression vector
项目摘要
DESCRIPTION (provided by applicant): This application is a continuation on our studies of normal and abnormal hemoglobin synthesis in sickle cell anemia and thalassemia. The project in the previous grant period consisted of three aims. 1) DNA diagnosis of sickle cell anemia and thalassemia. 2) Control of globin gene expression. 3) Globin gene transfer. Because the topics in Aim 2 will now be carried on by previous trainees who have become independent investigators, this proposal will continue to pursue only the first and third aims. hi Aim 1 we have completed our studies on dot blot hybridization for the diagnosis of the mutations in hemoglobinopathies and thalassemia that are commonly found in the American population. We propose to develop and refine methods of prenatal diagnosis from fetal cells isolated using maternal blood. Our preliminary studies show that this is a promising approach, but much more work is needed to make this test practical. We will use phage display to isolate single chain antibodies specific for fetal nucleated red cells and human embryonic hemoglobin. We will investigate the use of image analysis and laser capture microdissections to facilitate the retrieval of fetal nucleated red cells. These developments will greatly enhance the usefulness of this procedure. The second aim of this proposal is to explore the possibility of in utero gene delivery alpha-thalassemia is a good model for in utero gene therapy because pathological changes in homozygous alpha-thalassemia usually appear before birth. In our laboratory, we have made mouse models of alpha-thalassemia by knocking out the endogenous mouse alpha-globin genes. By crossing various strains, we have mice that have 3,2,1 or no alpha-globin gene and they mimic the clinical manifestation of human alpha-thalassemia. We will use AAV vectors and lentiviral vectors containing the beta-g1obin LCR controlling the human a-globin gene to inject into fetal mice at the 15th week of gestation. We will follow these mice to observe the expression of the. alpha-globin gene and the rescue the disease phenotype. Such an approach could be useful not only for alpha-thalassemia but also for other genetic disorders such as OTC deficiency where the disease begins in utero.
描述(由申请人提供):本申请是我们对镰状细胞性贫血和地中海贫血中正常和异常血红蛋白合成研究的继续。上一个赠款期的项目包括三个目标。1)镰状细胞性贫血和地中海贫血的DNA诊断。2)珠蛋白基因表达的控制。3)珠蛋白基因转移。由于目标2中的主题现在将由已成为独立调查员的以前的受训人员继续进行,因此本提案将继续只追求第一和第三个目标。目的1:我们已经完成了斑点杂交诊断血红蛋白病和地中海贫血突变的研究,这些突变在美国人群中很常见。我们建议开发和完善的产前诊断方法,从胎儿细胞分离使用母体血液。我们的初步研究表明,这是一种很有前途的方法,但还需要做更多的工作,使这种测试实用。我们将利用噬菌体展示技术来分离针对胎儿有核红细胞和人胚胎血红蛋白的单链抗体。我们将探讨使用图像分析和激光捕获显微切割,以促进胎儿有核红细胞的检索。这些发展将大大提高这一程序的效用。该建议的第二个目的是探索宫内基因递送的可能性,因为纯合子α-地中海贫血的病理变化通常在出生前出现,所以α-地中海贫血是宫内基因治疗的良好模型。在我们的实验室中,我们通过敲除内源性小鼠α-珠蛋白基因来制作α-地中海贫血小鼠模型。通过杂交不同的品系,我们得到了具有3,2,1或没有α-珠蛋白基因的小鼠,它们模仿了人类α-地中海贫血的临床表现。我们将使用含有控制人α-珠蛋白基因的β-珠蛋白LCR的AAV载体和慢病毒载体注射到妊娠第15周的胎鼠中。我们将跟踪观察这些小鼠的表达。α-珠蛋白基因和拯救疾病表型。这种方法不仅适用于α-地中海贫血,而且适用于其他遗传性疾病,如OTC缺乏症,这种疾病始于子宫内。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YUET Wai KAN其他文献
YUET Wai KAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YUET Wai KAN', 18)}}的其他基金
Reprogramming iPS Cells with Exogenous and Endogenous Transcription Factor Genes
使用外源和内源转录因子基因重编程 iPS 细胞
- 批准号:
8917047 - 财政年份:2015
- 资助金额:
$ 43.5万 - 项目类别:
Reprogramming iPS Cells with Exogenous and Endogenous Transcription Factor Genes
使用外源和内源转录因子基因重编程 iPS 细胞
- 批准号:
8710193 - 财政年份:2014
- 资助金额:
$ 43.5万 - 项目类别:
Development of iPS Cells for Treatment of Hemoglobinopathies
开发用于治疗血红蛋白病的 iPS 细胞
- 批准号:
8710192 - 财政年份:2011
- 资助金额:
$ 43.5万 - 项目类别:
Development of iPS Cells for Treatment of Hemoglobinopathies
开发用于治疗血红蛋白病的 iPS 细胞
- 批准号:
8332252 - 财政年份:2011
- 资助金额:
$ 43.5万 - 项目类别:
Development of iPS Cells for Treatment of Hemoglobinopathies
开发用于治疗血红蛋白病的 iPS 细胞
- 批准号:
8150802 - 财政年份:2011
- 资助金额:
$ 43.5万 - 项目类别:
Development of iPS Cells for Treatment of Hemoglobinopathies
开发用于治疗血红蛋白病的 iPS 细胞
- 批准号:
8532884 - 财政年份:2011
- 资助金额:
$ 43.5万 - 项目类别:
Development of iPS Cells for Treatment of Hemoglobinopathies
开发用于治疗血红蛋白病的 iPS 细胞
- 批准号:
8917036 - 财政年份:2011
- 资助金额:
$ 43.5万 - 项目类别:
FETAL MONKEY MODEL FOR GENE THERAPY FOR SICKLE CELL DISEASE
用于镰状细胞病基因治疗的胎猴模型
- 批准号:
7715557 - 财政年份:2008
- 资助金额:
$ 43.5万 - 项目类别:
FETAL MONKEY MODEL FOR GENE THERAPY FOR SICKLE CELL DISEASE
用于镰状细胞病基因治疗的胎猴模型
- 批准号:
7562145 - 财政年份:2007
- 资助金额:
$ 43.5万 - 项目类别:
FETAL MONKEY MODEL FOR GENE THERAPY FOR SICKLE CELL DISEASE
用于镰状细胞病基因治疗的胎猴模型
- 批准号:
7349628 - 财政年份:2006
- 资助金额:
$ 43.5万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 43.5万 - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
- 批准号:
10828252 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别: